1. Home
  2. KSS vs OLMA Comparison

KSS vs OLMA Comparison

Compare KSS & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$12.49

Market Cap

2.2B

ML Signal

HOLD

Logo Olema Pharmaceuticals Inc.

OLMA

Olema Pharmaceuticals Inc.

HOLD

Current Price

$13.66

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
OLMA
Founded
1962
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
KSS
OLMA
Price
$12.49
$13.66
Analyst Decision
Sell
Strong Buy
Analyst Count
15
9
Target Price
$15.31
$44.89
AVG Volume (30 Days)
5.2M
1.6M
Earning Date
03-10-2026
03-16-2026
Dividend Yield
3.87%
N/A
EPS Growth
142.86
15.00
EPS
2.38
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.09
$347.47
P/E Ratio
$5.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.04
$2.86
52 Week High
$25.22
$36.26

Technical Indicators

Market Signals
Indicator
KSS
OLMA
Relative Strength Index (RSI) 33.83 27.43
Support Level $12.04 $4.15
Resistance Level $16.95 $27.38
Average True Range (ATR) 0.84 1.07
MACD 0.07 0.00
Stochastic Oscillator 9.81 16.67

Price Performance

Historical Comparison
KSS
OLMA

About KSS Kohl's Corporation

Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: